Sangamo enters into asset sale agreements with Lilly and Astellas

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Zinc Finger Nuclease/AAV6-Mediated Factor IX(FIX) Insertion Into B Cells Results in Sustained Therapeutic FIX Levels In Vivo After Using a GMP-Like Differentiation Culture System

Download PDF